390P - Systematic review and meta-analysis of pediatric head and neck squamous cell carcinoma (PHNSCC): An analysis of 217 cases

Date 17 December 2016
Event ESMO Asia 2016 Congress
Session Poster lunch
Topics Cancer in Special Situations
Head and Neck Cancers
Presenter Bhanu Venkatesulu
Citation Annals of Oncology (2016) 27 (suppl_9): ix112-ix122. 10.1093/annonc/mdw587
Authors B.P. Venkatesulu1, S. Mallick2, A.G.F. Thoyattan1, G.K. Rath2
  • 1Radiation Oncology, All India Institute of Medical Sciences, 110029 - New Delhi/IN
  • 2Radiotherapy, All India Institute of Medical Sciences, 110029 - Delhi/IN



HNSCC is rare entity in pediatric age group (≤ 20 years as defined by the American college of Pediatrics). We intended to perform this review of published literature to assess the demographic profile, pattern of care and assess survival outcomes.


Two authors (BP and SM) independently searched PubMed, google search, and Cochrane library for eligible studies till June 1 2016 published in English language.


Median age among the cohort was 15 years (Range: 0-20 years). 20.56% (22) patients were below 10 years of age and 79.44% (85) of were between 11-20 years of age. Sex ratio was skewed in favor of males with ratio of 1.7:1 and number were male 66(63.46%) and female 38(36.53%). Majority of patients were of oral cavity tumors 75 (70%) followed by laryngeal neoplasms 16(15%).11(10.2%) patients had DNA repair defect fanconis anemia .Median disease free survival was 9 months (Range: 0-216 months). 2 and 5 year DFS for oral cavity and non-oral cavity primary was 75.7%, 75.7% and 65.3%, 65.3% respectively. (p = 0.31). 5 year disease free survival (DFS) was 87.2% for patients treated with surgery only and 67.1% for patients treated with surgery followed by adjuvant radiation. Whereas 5year DFS was 28.5%, for patients treated with radiation alone p = 0.0013. 5 year DFS for stage 1, 2, 3 were 86.6%, 78.5% and 40.8% respectively; p = 0.11. 2 and 5 year DFS for the entire cohort was 72.27% [95% CI: 0.59 - 0.81)] and 72.27% [95% CI: 0.59 - 0.81)]. Age, time of publication, sex, associated syndromes had no significant impact on DFS. Median overall survival was 48 months (Range: 1-216 months). 2 and 5 year OS was 57.46% [95%CI: 0.44-0.68] and 44.77% [95% CI: 0.28-0.59] respectively. 5 year OS for patients treated with surgery alone, or surgery followed by adjuvant radiation, radiotherapy alone was 49.62%, 68.57% and 22.22% respectively.


PHNSCC is extremely rare entity with distinct challenges to the physician and care givers. Surgery was the primary modality with best outcomes.PHNSCC with DNA repair defects has poor outcomes with dismal prognosis.

Clinical trial indentification

Legal entity responsible for the study

Bhanu Prasad venkatesulu


All India Institute of Medical Sciences


All authors have declared no conflicts of interest.